Sarah Kane
Associate Director, HEOR
Expertise:
Sarah has 10+ years of professional experience across biotechnology and HEOR sectors. Within the Value & Evidence team at EVERSANA, Sarah supports numerous aspects of HEOR, including economic modelling, systematic literature reviews, meta-analyses and value communications.
Sarah joined EVERSANA after 4+ years in the biotechnology sector where she was involved in a wide range of projects including development of a commercial canine probiotic, microbial food sampling, and pharmaceutical product development. She holds a Ph.D. in Molecular Microbiology from the University of Alberta and a B.Sc. in Biomedical Science from the University of Waterloo.
Since joining EVERSANA, Sarah has been involved in a variety of projects including cost calculator/model development (Excel BIM/CUA and BaseCase), literature reviews (structured and systematic), meta-analyses, development of various value communication tools and preparation of interactive slide decks, sales force tools, manuscripts, and abstracts.
Sarah has experience across a variety of therapeutic areas spanning cardiovascular disease, neurovascular disease, ophthalmology, oncology and hematology.
Articles by Sarah Kane
Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced/metastatic breast cancer (HR+/HER2- LABC/mBC) in the first-line (1L) treatment setting. However, there is no clear standard of care for patients after 1L CDK4/6i treatment. Understanding the real-world effectiveness of subsequent therapies may help to identify an unmet need in this patient population. The Value & Evidence team at EVERSANA (Sarah Kane, Belal Howidi, Ngoc Nguyen, Joanna Bielecki and Imtiaz A. Samjoo) synthesized the effectiveness of treatments received in the real-world setting […]
Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC
Lung cancer is one of the most incident malignancies and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and, with the emergence of genomic techniques, tumor genotyping has led to the identification of actionable driver alterations in NSCLC. The ROS1 gene encodes a tyrosine kinase receptor that plays an important role in the activation of several signaling pathways associated with cellular differentiation, proliferation, growth and survival. ROS1 gene rearrangement is rare and is detected as an oncogenic driver in 0.9% to 2.6% of NSCLC cases. Crizotinib was first approved for ROS1 advanced NSCLC (aNSCLC) in the United States in […]